Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.090
-0.010 (-0.91%)
At close: Sep 17, 2025, 4:00 PM EDT
1.081
-0.010 (-0.87%)
After-hours: Sep 17, 2025, 7:27 PM EDT
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 103 employees as of December 31, 2024. The number of employees decreased by 182 or -63.86% compared to the previous year.
Employees
103
Change (1Y)
-182
Growth (1Y)
-63.86%
Revenue / Employee
$567,301
Profits / Employee
-$1,171,068
Market Cap
396.10M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103 | -182 | -63.86% |
Dec 31, 2023 | 285 | 150 | 111.11% |
Dec 31, 2022 | 135 | 48 | 55.17% |
Dec 31, 2021 | 87 | 9 | 11.54% |
Dec 31, 2020 | 78 | -106 | -57.61% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LXRX News
- 13 hours ago - Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings - GlobeNewsWire
- 6 days ago - Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings - GlobeNewsWire
- 9 days ago - Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - GlobeNewsWire
- 13 days ago - Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 - GlobeNewsWire
- 14 days ago - Lexicon Pharmaceuticals, Inc. (LXRX) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 14 days ago - Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 - GlobeNewsWire
- 15 days ago - Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress - GlobeNewsWire
- 21 days ago - Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences - GlobeNewsWire